MiRNA-based Therapeutics for Lung Cancer

Author(s): Miaowei Wu*, Guosheng Wang*, Wei Tian, Yongchuan Deng, Yibing Xu

Journal Name: Current Pharmaceutical Design

Volume 23 , Issue 39 , 2017

Become EABM
Become Reviewer
Call for Editor


Background: miRNA, a small non-coding RNA molecule containing about 22 nucleotides, functions in RNA silencing and post-transcriptional regulation of gene expression. With these qualities, miRNAs modulate multiple signaling pathways involved in cancer development, such as cellular proliferation, apoptosis, and migration.

Methods: The goal of this review is to discuss possible miRNAs-based therapeutic strategies, through defining performance of miRNAs in carcinogenesis, in particular in lung cancer.

Results: miRNA, a non-coding RNA, is divided into two main types: tumor suppressor miRNAs and oncogenic miRNAs. In addition, special processed miRNAs can be an assistant therapeutic tool.

Conclusion: In order to develope antitumor therapy, miRNAs-based therapeutic strategies are worth of deeper studies. In this process, the stability, effectiveness, and side effects should be considered.

Keywords: miRNA, oncogene, tumor suppressor, drug resistance, lung cancer, therapy.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Published on: 12 February, 2018
Page: [5989 - 5996]
Pages: 8
DOI: 10.2174/1381612823666170714151715
Price: $65

Article Metrics

PDF: 24